188 related articles for article (PubMed ID: 38113030)
1. LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development.
Huang R; Liu X; Kim J; Deng H; Deng M; Gui X; Chen H; Wu G; Xiong W; Xie J; Lewis C; Homsi J; Yang X; Zhang C; He Y; Lou Q; Smith C; John S; Zhang N; An Z; Zhang CC
Cancer Immunol Res; 2024 Mar; 12(3):350-362. PubMed ID: 38113030
[TBL] [Abstract][Full Text] [Related]
2. LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2-cFLIP-NF-κB signaling axis.
Wu G; Xu Y; Schultz RD; Chen H; Xie J; Deng M; Liu X; Gui X; John S; Lu Z; Arase H; Zhang N; An Z; Zhang CC
Nat Cancer; 2021 Nov; 2(11):1170-1184. PubMed ID: 35122056
[TBL] [Abstract][Full Text] [Related]
3. LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy.
Mai S; Hodges A; Chen HM; Zhang J; Wang YL; Liu Y; Nakatsu F; Wang X; Fang J; Xu Y; Davidov V; Kang K; Pingali SR; Ganguly S; Suzuki M; Konopleva M; Prinzing B; Zu Y; Gottschalk S; Lu Y; Chen SH; Pan PY
Cancer Res; 2023 Dec; 83(24):4047-4062. PubMed ID: 38098451
[TBL] [Abstract][Full Text] [Related]
4. LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Yeboah M; Papagregoriou C; Jones DC; Chan HTC; Hu G; McPartlan JS; Schiött T; Mattson U; Mockridge CI; Tornberg UC; Hambe B; Ljungars A; Mattsson M; Tews I; Glennie MJ; Thirdborough SM; Trowsdale J; Frendeus B; Chen J; Cragg MS; Roghanian A
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32870822
[TBL] [Abstract][Full Text] [Related]
5. Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma.
Fan J; Li J; Han J; Zhang Y; Gu A; Song F; Duan J; Yin D; Wang L; Yi Y
Mol Immunol; 2021 Aug; 136():82-97. PubMed ID: 34098344
[TBL] [Abstract][Full Text] [Related]
6. Chicken novel leukocyte immunoglobulin-like receptor subfamilies B1 and B3 are transcriptional regulators of major histocompatibility complex class I genes and signaling pathways.
Truong AD; Hong Y; Lee J; Lee K; Tran HTT; Dang HV; Nguyen VK; Lillehoj HS; Hong YH
Asian-Australas J Anim Sci; 2019 May; 32(5):614-628. PubMed ID: 30381742
[TBL] [Abstract][Full Text] [Related]
7. Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies.
Luo W; Napoleon JV; Zhang F; Lee YG; Wang B; Putt KS; Low PS
Front Immunol; 2022; 13():816761. PubMed ID: 35250995
[TBL] [Abstract][Full Text] [Related]
8. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance.
Ajith A; Mamouni K; Horuzsko DD; Musa A; Dzutsev AK; Fang JR; Chadli A; Zhu X; Lebedyeva I; Trinchieri G; Horuzsko A
J Clin Invest; 2023 Nov; 133(21):. PubMed ID: 37651197
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
Steggerda SM; Bennett MK; Chen J; Emberley E; Huang T; Janes JR; Li W; MacKinnon AL; Makkouk A; Marguier G; Murray PJ; Neou S; Pan A; Parlati F; Rodriguez MLM; Van de Velde LA; Wang T; Works M; Zhang J; Zhang W; Gross MI
J Immunother Cancer; 2017 Dec; 5(1):101. PubMed ID: 29254508
[TBL] [Abstract][Full Text] [Related]
10. LILRB receptor-mediated regulation of myeloid cell maturation and function.
van der Touw W; Chen HM; Pan PY; Chen SH
Cancer Immunol Immunother; 2017 Aug; 66(8):1079-1087. PubMed ID: 28638976
[TBL] [Abstract][Full Text] [Related]
11. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
[TBL] [Abstract][Full Text] [Related]
12. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.
Wang L; Hu D; Xie B; Xie L
Invest New Drugs; 2022 Jun; 40(3):506-518. PubMed ID: 35089465
[TBL] [Abstract][Full Text] [Related]
13. Diversity of the human LILRB3/A6 locus encoding a myeloid inhibitory and activating receptor pair.
Bashirova AA; Apps R; Vince N; Mochalova Y; Yu XG; Carrington M
Immunogenetics; 2014 Jan; 66(1):1-8. PubMed ID: 24096970
[TBL] [Abstract][Full Text] [Related]
14. Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells.
Ma G; Pan PY; Eisenstein S; Divino CM; Lowell CA; Takai T; Chen SH
Immunity; 2011 Mar; 34(3):385-95. PubMed ID: 21376641
[TBL] [Abstract][Full Text] [Related]
15. ILT2 and ILT4 Drive Myeloid Suppression via Both Overlapping and Distinct Mechanisms.
Tian J; Ashique AM; Weeks S; Lan T; Yang H; Chen HH; Song C; Koyano K; Mondal K; Tsai D; Cheung I; Moshrefi M; Kekatpure A; Fan B; Li B; Qurashi S; Rocha L; Aguayo J; Rodgers C; Meza M; Heeke D; Medfisch SM; Chu C; Starck S; Basak NP; Sankaran S; Malhotra M; Crawley S; Tran TT; Duey DY; Ho C; Mikaelian I; Liu W; Rivera LB; Huang J; Paavola KJ; O'Hollaren K; Blum LK; Lin VY; Chen P; Iyer A; He S; Roda JM; Wang Y; Sissons J; Kutach AK; Kaplan DD; Stone GW
Cancer Immunol Res; 2024 May; 12(5):592-613. PubMed ID: 38393969
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade.
Lin C; Ren W; Luo Y; Li S; Chang Y; Li L; Xiong D; Huang X; Xu Z; Yu Z; Wang Y; Zhang J; Huang C; Xia N
Cancer Immunol Res; 2020 May; 8(5):632-647. PubMed ID: 32127389
[TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Feng S; Cheng X; Zhang L; Lu X; Chaudhary S; Teng R; Frederickson C; Champion MM; Zhao R; Cheng L; Gong Y; Deng H; Lu X
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10094-10099. PubMed ID: 30232256
[TBL] [Abstract][Full Text] [Related]
18. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
Front Immunol; 2018; 9():398. PubMed ID: 29552012
[TBL] [Abstract][Full Text] [Related]
19. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
20. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
